Insilico Medicine Featured in Harvard Business School Case Study on Rentosertib

The page describes Insilico's DDR1 kinase inhibitor proof-of-concept for fibrosis: using its generative Tensorial Reinforcement Learning (GENTRL) approach and Chemistry42 platform, Insilico identified potent inhibitors in 21 days, with synthesis and testing completed within 35 days total, achieving two-digit nanomolar activity (10 nM and 21 nM). This work was published in Nature Biotechnology in 2019 under the title "Deep learning enables rapid identification of potent DDR1 kinase inhibitors."

Insilico Medicine is an AI-native biotech running its own generative-chemistry drug-discovery platform (Pharma.AI), and licensing it through partnerships with major pharma companies.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.